Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238765974> ?p ?o ?g. }
- W4238765974 endingPage "125" @default.
- W4238765974 startingPage "114" @default.
- W4238765974 abstract "Background: Cyclooxygenase-2-specific anti-inflammatory drugs (coxibs) and nonspecific nonsteroidal anti-inflammatory drugs have been shown to inhibit experimental fracture-healing. The present study tested the hypothesis that these effects are reversible after short-term treatment. Methods: With use of a standard model of fracture-healing, identical ED50 dosages of either a nonsteroidal anti-inflammatory drug (ketorolac), a coxib (valdecoxib), or vehicle (control) were orally administered to rats for either seven or twenty-one days and fracture-healing was assessed with biomechanical, histological, and biochemical analyses. Results: When healing was assessed at twenty-one days, the seven-day treatment produced only a trend for a higher rate of nonunion in valdecoxib and ketorolac-treated animals as compared with controls. No differences were observed at thirty-five days. The twenty-one-day treatment produced significantly more nonunions in valdecoxib-treated animals as compared with either ketorolac-treated or control animals (p < 0.05), but these differences disappeared by thirty-five days. The dose-specific inhibition of these drugs on prostaglandin E2 levels and the reversibility of the effects after drug withdrawal were assessed in fracture calluses and showed that ketorolac treatment led to twofold to threefold lower levels of prostaglandin E2 than did valdecoxib. Withdrawal of either drug after six days led to a twofold rebound in these levels by fourteen days. Histological analysis showed delayed remodeling of calcified cartilage and reduced bone formation in association with valdecoxib treatment. Conclusions: Cyclooxygenase-2-specific drugs inhibit fracture-healing more than nonspecific nonsteroidal anti-inflammatory drugs, and the magnitude of the effect is related to the duration of treatment. However, after the discontinuation of treatment, prostaglandin E2 levels are gradually restored and the regain of strength returns to levels similar to control. Clinical Relevance: While animal studies have suggested that both nonsteroidal anti-inflammatory drugs and coxibs inhibit bone repair, there have been no clinical reports with Level-1 evidence to support these findings. Because most patients discontinue these medications when pain has subsided, it is important to determine whether the inhibitory effects are reversible. The present animal study confirms that inhibition of cyclooxygenase 2 impairs fracture-healing and that the effects are dependent on both the dose and duration of treatment. However, the reduced prostaglandin levels in callus rebound with drug withdrawal, and the impairment in the mechanical integrity of the healing fractures is reversed after short-term treatment." @default.
- W4238765974 created "2022-05-12" @default.
- W4238765974 creator A5005029704 @default.
- W4238765974 creator A5006498611 @default.
- W4238765974 creator A5040334425 @default.
- W4238765974 creator A5041583266 @default.
- W4238765974 creator A5041819903 @default.
- W4238765974 creator A5044557394 @default.
- W4238765974 creator A5053051638 @default.
- W4238765974 creator A5063351158 @default.
- W4238765974 creator A5079388461 @default.
- W4238765974 date "2007-01-01" @default.
- W4238765974 modified "2023-10-01" @default.
- W4238765974 title "Selective and Nonselective Cyclooxygenase-2 Inhibitors and Experimental Fracture-Healing" @default.
- W4238765974 cites W1892257529 @default.
- W4238765974 cites W1967495045 @default.
- W4238765974 cites W1974280648 @default.
- W4238765974 cites W1979242330 @default.
- W4238765974 cites W1984588551 @default.
- W4238765974 cites W1984701700 @default.
- W4238765974 cites W1985298426 @default.
- W4238765974 cites W2001162433 @default.
- W4238765974 cites W2012571546 @default.
- W4238765974 cites W2018716226 @default.
- W4238765974 cites W2020563114 @default.
- W4238765974 cites W2025061038 @default.
- W4238765974 cites W2026230456 @default.
- W4238765974 cites W2032491472 @default.
- W4238765974 cites W2052192250 @default.
- W4238765974 cites W2053475304 @default.
- W4238765974 cites W2073184155 @default.
- W4238765974 cites W2080178855 @default.
- W4238765974 cites W2092193486 @default.
- W4238765974 cites W2102254877 @default.
- W4238765974 cites W2135231814 @default.
- W4238765974 cites W2140908408 @default.
- W4238765974 cites W2149233326 @default.
- W4238765974 cites W2154879871 @default.
- W4238765974 cites W2176101211 @default.
- W4238765974 cites W2395704271 @default.
- W4238765974 cites W2725056820 @default.
- W4238765974 cites W28782474 @default.
- W4238765974 cites W2988816971 @default.
- W4238765974 cites W4236708194 @default.
- W4238765974 cites W4251038979 @default.
- W4238765974 cites W4255366786 @default.
- W4238765974 doi "https://doi.org/10.2106/00004623-200701000-00016" @default.
- W4238765974 hasPublicationYear "2007" @default.
- W4238765974 type Work @default.
- W4238765974 citedByCount "29" @default.
- W4238765974 countsByYear W42387659742012 @default.
- W4238765974 countsByYear W42387659742013 @default.
- W4238765974 countsByYear W42387659742015 @default.
- W4238765974 countsByYear W42387659742016 @default.
- W4238765974 countsByYear W42387659742017 @default.
- W4238765974 countsByYear W42387659742018 @default.
- W4238765974 countsByYear W42387659742019 @default.
- W4238765974 countsByYear W42387659742020 @default.
- W4238765974 countsByYear W42387659742021 @default.
- W4238765974 crossrefType "journal-article" @default.
- W4238765974 hasAuthorship W4238765974A5005029704 @default.
- W4238765974 hasAuthorship W4238765974A5006498611 @default.
- W4238765974 hasAuthorship W4238765974A5040334425 @default.
- W4238765974 hasAuthorship W4238765974A5041583266 @default.
- W4238765974 hasAuthorship W4238765974A5041819903 @default.
- W4238765974 hasAuthorship W4238765974A5044557394 @default.
- W4238765974 hasAuthorship W4238765974A5053051638 @default.
- W4238765974 hasAuthorship W4238765974A5063351158 @default.
- W4238765974 hasAuthorship W4238765974A5079388461 @default.
- W4238765974 hasConcept C126322002 @default.
- W4238765974 hasConcept C141071460 @default.
- W4238765974 hasConcept C181199279 @default.
- W4238765974 hasConcept C185592680 @default.
- W4238765974 hasConcept C2777956040 @default.
- W4238765974 hasConcept C2778446825 @default.
- W4238765974 hasConcept C2778484676 @default.
- W4238765974 hasConcept C2778582115 @default.
- W4238765974 hasConcept C2779528491 @default.
- W4238765974 hasConcept C2779689624 @default.
- W4238765974 hasConcept C2780820201 @default.
- W4238765974 hasConcept C42219234 @default.
- W4238765974 hasConcept C55493867 @default.
- W4238765974 hasConcept C71924100 @default.
- W4238765974 hasConcept C8337478 @default.
- W4238765974 hasConcept C98274493 @default.
- W4238765974 hasConceptScore W4238765974C126322002 @default.
- W4238765974 hasConceptScore W4238765974C141071460 @default.
- W4238765974 hasConceptScore W4238765974C181199279 @default.
- W4238765974 hasConceptScore W4238765974C185592680 @default.
- W4238765974 hasConceptScore W4238765974C2777956040 @default.
- W4238765974 hasConceptScore W4238765974C2778446825 @default.
- W4238765974 hasConceptScore W4238765974C2778484676 @default.
- W4238765974 hasConceptScore W4238765974C2778582115 @default.
- W4238765974 hasConceptScore W4238765974C2779528491 @default.
- W4238765974 hasConceptScore W4238765974C2779689624 @default.
- W4238765974 hasConceptScore W4238765974C2780820201 @default.
- W4238765974 hasConceptScore W4238765974C42219234 @default.
- W4238765974 hasConceptScore W4238765974C55493867 @default.